Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W

Young Kwang Chae,Fangxin Hong,Christos Vaklavas,Heather H. Cheng,Peter S. Hammerman,Edith P. Mitchell,James A. Zwiebel,S. Percy Ivy,Robert Gray,Shuli Li,Lisa M. McShane,Larry Rubinstein,David Patton,P. Mickey Williams,Stanley R. Hamilton,Aaron S. Mansfield,Barbara A. Conley,Carlos L. Arteaga,Lyndsay Harris,Peter J. ODwyer,Alice P. Chen,Keith T. Flaherty

Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W

2020

PURPOSENCI-MATCH is a nationwide, histology-agnostic, signal-finding, molecular profile–driven trial for patients with refractory cancers, lymphomas, or myelomas. Patients with tumors harboring act...

Keywords:

Phases of clinical research
Oncology
Internal medicine
Fibroblast growth factor receptor
MEDLINE
Refractory
Medicine
in patient
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations